
Servier licenses Pfizer US rights to leukemia compound
Executive Summary
Servier SA granted Pfizer Inc. exclusive rights to develop and commercialize the preclinical leukemia candidate UCART19 in the US.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com